Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance

Journal of Diabetes Science and Technology

Volumn 7, Issue 4, 2013, Pages 990-1000

  Olson, Byron P ^a   Matter, Nathaniel I ^a   Ediger, Marwood N ^a   Hull, Edward L ^a   Maynard, John D ^a  

^a VeraLight Inc   (United States)

Author keywords

Abnormal glucose tolerance; Diabetes screening; Fluorescence; Noninvasive; SCOUT DS

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABNORMAL GLUCOSE TOLERANCE; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; FASTING PLASMA GLUCOSE; FEMALE; FLUORESCENCE SPECTROSCOPY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SKIN FLUORESCENCE SPECTROSCOPY; WAIST CIRCUMFERENCE; ADOLESCENT; ANALYSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MASS SCREENING; MIDDLE AGED; PATHOPHYSIOLOGY; PREDIABETIC STATE; PROCEDURES; SKIN; SPECTROFLUOROMETRY; YOUNG ADULT; METHODOLOGY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDIABETIC STATE; SKIN; SPECTROMETRY, FLUORESCENCE; YOUNG ADULT;

EID: 84897119515     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700422     Document Type: Article

References (34)

1. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross sectional population study. BMJ. 2001;323(7312):548-51. (Pubitemid 32835576)
2. Eborall H, Stone M, Aujla N, Taub N, Davies M, Khunti K. Influences on the uptake of diabetes screening: a qualitative study in primary care. Br J Gen Pract. 2012;62(596):e204-11.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36 Suppl 1:S67-74.
4. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med. 2010;27(9):995-1003.
5. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care. 2002;25(10):1784-9. (Pubitemid 41071087)
6. Khunti K, Gillies CL, Taub NA, Mostafa SA, Hiles SL, Abrams KR, Davies MJ. A comparison of cost per case detected of screening strategies for type 2 diabetes and impaired glucose regulation: Modelling study. Diabetes Res Clin Pract. 2012;97(3):505-13.
7. Ediger MN, Olson BP, Maynard JD. Noninvasive Optical Screening for Diabetes. J Diabetes Sci Technol. 2009;3(4):776-80.
8. Hull E, Ediger M, Unione A, Deemer E, Stroman M, Baynes J. Noninvasive, optical detection of diabetes: model studies with porcine skin. Opt Express. 2004;12(19):4496-510.
9. Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol Ther. 2011;13(7):773-9.
10. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and ageinduced diabetes in mice. Cell Metab. 2011;14(4):528-36.
11. Heikal AA. Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies. Biomark Med. 2010;4(2):241-63.
12. Ediger MN, Maynard JD. Noninvasive optical detection of impaired glucose tolerance: a comparison against FPG and A1C. Rev Endocrinol. 2007:62-4.
13. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care. 2007;30(5):1120-4. (Pubitemid 46684635)
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2012. Diabetes Care. 2012;35 Suppl 1:S11-63.
15. Centers for Disease Control and Prevention. National health and nutrition examination survey: NHANES III. http://www.cdc.gov/nchs/nhanes/nh3data.htm#1a.
16. Centers for Disease Control and Prevention. National health and nutrition examination survey: NHANES 2005 - 2006 laboratory files. http://www.cdc.gov/ nchs/nhanes/nhanes2005-2006/lab05-06.htm.
17. Centers for Disease Control and Prevention. National health and nutrition examination survey: NHANES 2007 - 2008 laboratory files. http://www.cdc.gov/ nchs/nhanes/nhanes2007-2008/lab07-08.htm.
18. Robles-Osorio L, Aguilar-Salinas CA, Mehta R, Gómez-Pérez FJ, Rull JA. Analysis of fasting plasma glucose values for optimal detection of abnormal responses on the oral glucose tolerance test in at-risk study subjects. Endocr Pract. 2007;13(6):583-9.
19. Dodd LE, Pepe MS. Partial AUC estimation and regression. Biometrics. 2003;59(3):614-23. (Pubitemid 37093400)
20. Qin G, Jin X, Zhou X. Non-parametric interval estimation for partial area under the ROC curve. Canadian J Statistics. 2011;39:17-33.
21. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39(3):298-305. (Pubitemid 26066801)
22. Hull E, Matter N, Olson B, Ediger M, Magee A, Way J, Maynard J. Noninvasive prediabetes and diabetes screening using skin fluorescence: clinical validation in an at-risk cohort. Presented at: Annual Meeting of the Canadian Diabetes Association, Toronto, ON, Canada, October 26-29, 2011.
23. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23(12):1830-4.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-65.
26. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920-4. (Pubitemid 29241045)
27. Norhammar A, Tenerz Å, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359(9324):2140-4. (Pubitemid 34694020)
28. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23(12):1830-4.
29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393-403. (Pubitemid 34437694)
30. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med. 2001;344(18):1343-50. (Pubitemid 32378388)
31. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677- 86.
32. Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care. 2010;33(7):1484-90.
33. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723-30.
34. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004;47(9):1566-73. (Pubitemid 39371639)